CORDIS
EU research results

CORDIS

English EN

European Lead Factory

Project information

Grant agreement ID: 115489

Status

Closed project

  • Start date

    1 January 2013

  • End date

    31 May 2018

Funded under:

FP7-JTI

  • Overall budget:

    € 194 305 900

  • EU contribution

    € 79 999 157

Coordinated by:

BAYER AKTIENGESELLSCHAFT

Germany

Objective

The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as starting points for subsequent optimization to either drug candidates or high-quality pharmacological tools for the experimental validation of targets. The concept intends to bridge academic and applied research interests. The European Lead Factory will provide an industry-like small molecule discovery platform to public investigators. It builds on a unique, comprehensive, high-quality compound collection contributed by EFPIA Pparticipants, i.e. the Pharma Consortium Compound Collection totaling over about 300.000 compounds. Screening of these previously safeguarded corporate compound libraries against competitor’s targets and targets from public sources may result in otherwise inaccessible valuable lead structures that could ultimately result in the development of novel treatment options for patients. Academic Participantsa or other eligible bodies (and Contributing Third Parties) will be invited to submit proposals for screening of innovative targets and to suggest the design of new and diverse chemical libraries utilizing novel concepts and strategies. The latter will fuel the generation of a Public Compound Collection that will combine with the Pharma ConsortiumEFPIA Compound Collection to generate the Joint European Compound CollectionLibrary. These public sector contributions will not only provide a constant flow of innovation, but also generate opportunities for future partnerships amongst public Public Participants and private contributors EFPIA Participants on scientific and commercial grounds. EUC2LID’s overarching goal is value creation by screening the Joint European Compound Collection Library against in pPublic and private EFPIA Ttarget Programmes. Based on the successful delivery on its objectives during the IMI funding period, the generation of the high quality Public Compound Collection provides a tangible asset allowing the transition of the European Lead Factory into a novel sustainable business model, facilitating future public-private alliances based on pre-competitive, community-based efforts in early drug research.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

BAYER AKTIENGESELLSCHAFT

Address

Kaiser-Wilhelm-Allee 1
51373 Leverkusen

Germany

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Principal Investigator

Stefan Jaroch (Dr.)

Administrative Contact

Petra Freitag (Ms)

Participants (32)

UNIVERSITEIT LEIDEN

Netherlands

EU Contribution

€ 828 076

BioCity Scotland Ltd

United Kingdom

EU Contribution

€ 2 198 018

PIVOT PARK SCREENING CENTRE BV

Netherlands

EU Contribution

€ 16 382 800

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 964 585

UNIVERSITY OF DUNDEE

United Kingdom

EU Contribution

€ 10 321 075

TAROS CHEMICALS GMBH & CO KG

Germany

EU Contribution

€ 7 444 995

MERCACHEM BV

Netherlands

EU Contribution

€ 5 254 347

LEAD DISCOVERY CENTER GMBH

Germany

EU Contribution

€ 474 698

EDELRIS SAS

France

EU Contribution

€ 5 097 700

SYNCOM BV

Netherlands

EU Contribution

€ 4 980 753

SYGNATURE DISCOVERY LIMITED

United Kingdom

EU Contribution

€ 5 114 237

GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG

Germany

EU Contribution

€ 451 477

STICHTING LYGATURE

Netherlands

EU Contribution

€ 2 778 883

THE UNIVERSITY OF NOTTINGHAM

United Kingdom

EU Contribution

€ 1 209 624

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS

Netherlands

EU Contribution

€ 401 449

UNIVERSITAET DUISBURG-ESSEN

Germany

EU Contribution

€ 779 096

STICHTING VU

Netherlands

EU Contribution

€ 820 434

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 2 053 986

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 800 748

DANMARKS TEKNISKE UNIVERSITET

Denmark

EU Contribution

€ 984 780

UNIVERSITY OF LEEDS

United Kingdom

EU Contribution

€ 1 532 940

RIJKSUNIVERSITEIT GRONINGEN

Netherlands

EU Contribution

€ 749 820

JANSSEN PHARMACEUTICA NV

Belgium

Merck KGaA

Germany

ASTRAZENECA AB

Sweden

SANOFI-AVENTIS DEUTSCHLAND GMBH

Germany

UCB PHARMA SA

Belgium

H. LUNDBECK AS

Denmark

ChemAxon Kutató-Fejlesztő Korlátolt Felelősségű Társaság

Hungary

EU Contribution

€ 370 200

BIOASCENT DISCOVERY LIMITED

United Kingdom

EU Contribution

€ 7 354 592

ARTTIC

France

EU Contribution

€ 254 123

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 395 721

Project information

Grant agreement ID: 115489

Status

Closed project

  • Start date

    1 January 2013

  • End date

    31 May 2018

Funded under:

FP7-JTI

  • Overall budget:

    € 194 305 900

  • EU contribution

    € 79 999 157

Coordinated by:

BAYER AKTIENGESELLSCHAFT

Germany